Effectiveness A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. Effectiveness is generally expected to slowly decrease over time. +Initial effectiveness by variant Doses Severity of illness Delta 1 Symptomatic Hospitalization 2 Symptomatic Hospitalization Efficacy A phase 3 clinical trial with 25,798 participants found that the vaccine is effective against asymptomatic cases, effective against symptomatic disease, effective against severe disease, and effective against the Delta variant.
Covaxin
Trafermin
Seviteronel
Rubitecan
Mecasermin
Dosulepin
Titermax
Itruvone